<DOC>
	<DOCNO>NCT02679508</DOCNO>
	<brief_summary>The purpose study exploratorily evaluate effect gastric mucosal tissue safety long-term administration ( 260 week : 5 year ) vonoprazan 10 mg 20 mg patient receive maintenance treatment heal erosive esophagitis ( EE ) , curative effect vonoprazan 20 mg versus lansoprazole patient EE .</brief_summary>
	<brief_title>Vonoprazan Study Patients With Erosive Esophagitis Evaluate Long-term Safety</brief_title>
	<detailed_description>This multicenter , open-label , randomize , parallel-group study exploratorily evaluate effect gastric mucosal tissue safety long-term administration vonoprazan maintenance treatment heal EE , curative effect vonoprazan versus lansoprazole participant EE . Participants endoscopically diagnose EE Los Angeles ( LA ) Classification Grades A D start treatment ( Week 0 heal phase ) randomly assign receive either vonoprazan 20 mg lansoprazole 30 mg take daily 8 week . Subjects heal EE confirm endoscopically Week 4 8 heal phase enter maintenance phase . In maintenance phase , vonoprazan group lansoprazole group administer start dose 10 mg 15 mg , respectively , daily 260 week . If principal investigator investigator judge effect vonoprazan 10 mg lansoprazole 15 mg insufficient maintenance treatment EE , vonoprazan lansoprazole may increase 20 mg 30 mg , respectively . The research period consist two subperiods : heal phase participant EE receive treatment ( 4 8 week ) maintenance phase participant receive maintenance treatment ( 260 week ) , thus , total 268 week . The number visit maximum 18 visit . Planned number research subject , number research subject entry maintenance phase , 130 participant vonoprazan group 65 participant lansoprazole group .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>Inclusion Criteria Healing Phase : 1 . Participants endoscopically diagnose EE grade A D LA Classification Grading System start treatment ( Week 0 heal phase ) 2 . Participants H. pylori negative 3 . Participants , opinion principal investigator investigator , capable understanding content clinical research comply research protocol requirement . 4 . Participants sign date inform consent form information sheet prior conduction clinical research procedure . 5 . Male female participant age 20 year old time inform consent 6 . Therapeutic category : Ambulatory Maintenance Phase : 7 . Participants endoscopically confirm EE healing* ( mucous membrane disorder observe ) completion heal phase ( Week 4 8 heal phase ) * Participants classify grade 0 accord severity classification EE ( See Table 9.b ) 8 . Participants determine appropriate subject maintenance treatment EE principal investigator investigator Healing Phase : 1 . Participants concurrent peptic ulcer ( except scar stage ) ZollingerEllison syndrome 2 . Participants receive treatment PPIs ( include vonoprazan ) within 4 week ( Week 4 Week 0 ) prior start heal phase ( Week 0 heal phase ) 3 . Participants history H. pylorus eradication . 4 . Participants receive surgery treatment affect gastroesophageal reflux ( fundoplication dilation esophageal stenosis [ exclude Schatzki 's ring ] , etc . ) 5 . Participants esophagusrelated complication ( eosinophilic esophagitis , esophageal varix , scleroderma , viral fungal infection , esophageal stenosis , etc . ) , history radiotherapy cryotherapy esophagus , caustic physiochemical trauma ( esophageal sclerotherapy , etc. ) . However , participant Schatzki 's ring ( mucosal tissue ring around inferior esophageal sphincter ) Barrett 's esophagus allow include . 6 . Participants clinically apparent hepatic impairment ( e.g. , AST ALT level time inform consent : &gt; 1.5 time upper limit normal ( ULN ) . 7 . Participants renal impairment renal failure [ creatinine clearance ( CCr ) Ë‚30 mL/min , etc . ] 8 . Participants history hypersensitivity allergy PPIs . 9 . Participants history gastrectomy , gastrointestinal resection , vagotomy 10 . Participants malignant tumor 11 . Participants pregnant , breastfeeding , possibly pregnant , plan become pregnant 12 . Participants one disease list administration contraindication vonoprazan lansoprazole package insert 13 . Participants plan take prohibit concomitant medication research period 14 . Participants participate clinical study 15 . Participants determine inappropriate subject study principal investigator investigator Maintenance Phase : 16 . Participants take PPIs study drug control drug heal phase 17 . Participants determine inappropriate subject study principal investigator investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Esophagitis</keyword>
</DOC>